Product Name | Ponatinib |
Description |
Tyrosine Kinase Inhibitors |
Purity | >98% (HPLC); NMR (conforms) |
CAS No. | 943319-70-8 |
Molecular Formula | C29H27F3N6O |
Molecular Weight | 532.6 |
Field of Use | Not for use in humans. Not for use in diagnostics or therapeutics. For in vitro research use only. |
Storage Temperature | -20ºC |
Shipping Temperature | Shipped Ambient |
Product Type | Inhibitor |
Solubility | May be dissolved in DMSO (50 mg/ml); or Ethanol (25 mg/ml, warm) |
Source | Synthetic |
Appearance | Yellow powder |
SMILES | CC1=C(C=C(C=C1)C(=O)NC2=CC(=C(C=C2)CN3CCN(CC3)C)C(F)(F)F)C#CC4=CN=C5N4N=CC=C5 |
InChI | InChI=1S/C29H27F3N6O/c1-20-5-6-22(16-21(20)8-10-25-18-33-27-4-3-11-34-38(25)27)28(39)35-24-9-7-23(26(17-24)29(30,31)32)19-37-14-12-36(2)13-15-37/h3-7,9,11,16-18H,12-15,19H2,1-2H3,(H,35,39) |
InChIKey | PHXJVRSECIGDHY-UHFFFAOYSA-N |
Safety Phrases |
May be harmful by inhalation, ingestion, or skin absorption. May cause eye, skin, or respiratory system irritation. |
Cite This Product | Ponatinib (StressMarq Biosciences Inc., Victoria BC CANADA, Catalog # SIH-588) |
Alternative Names | 3-(2-Imidazo[1,2-b]pyridazin-3-ylethynyl)-4-methyl-N-[4-[(4-methyl-1-piperazinyl)methyl]-3-(trifluoromethyl)phenyl]-benzamide, AP-24534 |
Research Areas | Cancer, Cancer Growth Inhibitors, Tyrosine Kinase Inhibitors |
PubChem ID | 24826799 |
Scientific Background |
Ponatinib is a multi-targeted tyrosine kinase inhibitor developed for resistant forms of leukemia. It inhibits BCR-ABL as well as kinases associated with VEGFR and FGFR signaling. Although not traditionally associated with neuroscience, Ponatinib’s inhibition of angiogenic and growth factor pathways has potential implications in brain tumor research and neurovascular disorders. Its ability to cross-inhibit multiple signaling cascades may also be relevant in neurodegenerative diseases where aberrant kinase activity contributes to neuronal dysfunction or glial proliferation. |
Reviews
There are no reviews yet.